Scientists have known that obesity and metabolic dysfunction can make cancers more aggressive. Tumors thrive in bodies ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, marketing its blockbuster semaglutide-based (GLP-1) drugs ...

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

In a 71-week, double-blind study, Nova Nordisk—creators of the popular weight loss drug Wegovy—says their oral semaglutide ...

When we talk about medications like Ozempic and Wegovy, the conversation often centres on weight loss, blood sugar control ...

Generic drugmaker Sandoz expects unbranded versions of Novo Nordisk's blockbuster diabetes drug Ozempic to launch in Canada ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1,350 a month. Under the ...

GLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients, according to a major UC San Diego study ...

Middle-class Indians trying to lose weight are embracing drugs such as Mounjaro, which is also used to treat diabetes in a ...

How Ozempic Is Changing Thanksgiving According to the independent research and polling source KFF, one in eight Americans reported taking a GLP-1 receptor agonist ...